세계의 인실리코 Drug Discocvery 시장 : 분자 유형, 워크플로우, 치료 영역, 최종 사용자별 예측(2025-2030년)

The In-Silico Drug Discovery Market was valued at USD 2.69 billion in 2023, expected to reach USD 2.86 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 4.83 billion by 2030.

In-silico drug discovery, which leverages computational methods to design and optimize drugs, is redefining the pharmaceutical landscape by accelerating the pace of drug development and reducing associated costs. It encompasses computer-aided drug design, molecular modeling, and simulations to predict interactions between drugs and their targets. The necessity of in-silico approaches stems from the pressing need to enhance R&D productivity, especially as traditional methods prove costly and time-consuming. These technologies find application in lead identification, optimization, and toxicity prediction, enhancing the precision of drug development. End-users primarily include pharmaceutical and biotechnology companies, research organizations, and academic institutions. The market is poised for growth, driven by significant prescriptive analytics advancements, enhanced processor capabilities, and escalating demand for personalized medicines. Additionally, the increasing adoption of AI and machine learning further boosts efficiency in drug discovery processes. A key opportunity lies in the burgeoning field of genomics, with in-silico tools facilitating personalized drug discovery tailored to genetic profiles, thereby attracting substantial research and investment. However, this market faces challenges such as high initial costs, data privacy concerns, and a shortage of skilled personnel proficient in computational methods. Technological limitations in accurately replicating the complexity of biological systems remain a hurdle. Innovations focusing on integrated platforms combining in-silico, in-vitro, and in-vivo data could provide competitive advantages. Cloud-based solutions for flexible modeling and collaboration also hold significant potential for transformative industry change. Companies should prioritize developing intuitive user interfaces and training programs to overcome the skills gap. Overall, while the in-silico drug discovery market presents a promising horizon with opportunities tied to technological advancement and integrated therapies, growth is contingent upon navigating economic and technical challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving In-Silico Drug Discovery Market

The In-Silico Drug Discovery Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of diseases and increase in drug discovery
  • Improvement in computational models and simulations
  • Inclination towards personalized medicine approach
• Market Restraints
  • Concerns associated with data integration
• Market Opportunities
  • Integration of advanced technologies in in-silico drug discovery
  • Ongoing R&D to drive innovation in in-silico drug discovery
• Market Challenges
  • Complex process and dearth of skilled professionals

Porter's Five Forces: A Strategic Tool for Navigating the In-Silico Drug Discovery Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the In-Silico Drug Discovery Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the In-Silico Drug Discovery Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the In-Silico Drug Discovery Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the In-Silico Drug Discovery Market

A detailed market share analysis in the In-Silico Drug Discovery Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the In-Silico Drug Discovery Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the In-Silico Drug Discovery Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the In-Silico Drug Discovery Market

A strategic analysis of the In-Silico Drug Discovery Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the In-Silico Drug Discovery Market, highlighting leading vendors and their innovative profiles. These include Abzena Ltd., Aragen Life Sciences Pvt. Ltd., BioDuro LLC, BioNTech SE, Certara, Inc., Charles River Laboratories International, Inc., Chemical Computing Group ULC, ChemPartner PharmaTech Co Ltd, Creative Biostructure, Curia Global Inc., Evotec SE, GenScript Biotech Corporation, InSilico Medicine, Ligand Pharmaceuticals Incorporated, Schrodinger Inc., Selvita S.A., Simulations Plus, Inc., Sygnature Discovery, Viva Biotech Holding Group, and WuXi AppTec.

Market Segmentation & Coverage

This research report categorizes the In-Silico Drug Discovery Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Molecule Type, market is studied across Antibodies, Nucleic Acids, Peptides, Proteins, and Vectors.
• Based on Workflow, market is studied across Bioinformatics, Clinical Trials, Discovery, Preclinical Tests, Protein Structure Prediction, Reverse Docking, and Target Identification.
• Based on Therapeutic Area, market is studied across Blood Disorders, Infectious Diseases, Mental Disorders, Metabolic Disorders, Musculoskeletal Disorders, Neurological Disorders, Oncological Disorders, Respiratory Disorders, and Skin Disorders.
• Based on End User, market is studied across Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical Manufacturers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of diseases and increase in drug discovery
    • 5.1.1.2. Improvement in computational models and simulations
    • 5.1.1.3. Inclination towards personalized medicine approach
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with data integration
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of advanced technologies in in-silico drug discovery
    • 5.1.3.2. Ongoing R&D to drive innovation in in-silico drug discovery
  • 5.1.4. Challenges
    • 5.1.4.1. Complex process and dearth of skilled professionals
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. In-Silico Drug Discovery Market, by Molecule Type

• 6.1. Introduction
• 6.2. Antibodies
• 6.3. Nucleic Acids
• 6.4. Peptides
• 6.5. Proteins
• 6.6. Vectors

7. In-Silico Drug Discovery Market, by Workflow

• 7.1. Introduction
• 7.2. Bioinformatics
• 7.3. Clinical Trials
• 7.4. Discovery
• 7.5. Preclinical Tests
• 7.6. Protein Structure Prediction
• 7.7. Reverse Docking
• 7.8. Target Identification

8. In-Silico Drug Discovery Market, by Therapeutic Area

• 8.1. Introduction
• 8.2. Blood Disorders
• 8.3. Infectious Diseases
• 8.4. Mental Disorders
• 8.5. Metabolic Disorders
• 8.6. Musculoskeletal Disorders
• 8.7. Neurological Disorders
• 8.8. Oncological Disorders
• 8.9. Respiratory Disorders
• 8.10. Skin Disorders

9. In-Silico Drug Discovery Market, by End User

• 9.1. Introduction
• 9.2. Academic & Research Institutes
• 9.3. Contract Research Organizations
• 9.4. Pharmaceutical Manufacturers

10. Americas In-Silico Drug Discovery Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific In-Silico Drug Discovery Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa In-Silico Drug Discovery Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abzena Ltd.
• 2. Aragen Life Sciences Pvt. Ltd.
• 3. BioDuro LLC
• 4. BioNTech SE
• 5. Certara, Inc.
• 6. Charles River Laboratories International, Inc.
• 7. Chemical Computing Group ULC
• 8. ChemPartner PharmaTech Co Ltd
• 9. Creative Biostructure
• 10. Curia Global Inc.
• 11. Evotec SE
• 12. GenScript Biotech Corporation
• 13. InSilico Medicine
• 14. Ligand Pharmaceuticals Incorporated
• 15. Schrodinger Inc.
• 16. Selvita S.A.
• 17. Simulations Plus, Inc.
• 18. Sygnature Discovery
• 19. Viva Biotech Holding Group
• 20. WuXi AppTec